JO
BCLI

John Overdeck’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

John Overdeck’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,145
Closed -$15.4K – 3150
2023
Q3 		$15.4K Buy
5,145
+1,877
+57% +$42.7K ﹤0.01% 2884
2023
Q2 		$101K Buy
+3,268
New +$135K ﹤0.01% 2757
2021
Q4 		– Sell
-1,060
Closed -$52K – 4278
2021
Q3 		$52K Sell
1,060
-2,143
-67% -$113K ﹤0.01% 4145
2021
Q2 		$183K Sell
3,203
-4,564
-59% -$244K ﹤0.01% 3805
2021
Q1 		$446K Buy
7,767
+1,819
+31% +$137K ﹤0.01% 3036
2020
Q4 		$404K Buy
+5,948
New +$810K ﹤0.01% 2647

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 22.73% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

John Overdeck's BCLI Position: Q4 2023 in Review

John Overdeck sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2023, closing a stake of 5,145 shares — an estimated $15.4K sold.

John Overdeck first reported a position in BCLI in Q4 2020 and held it in 6 quarters. The position peaked at $446K in Q1 2021. 46 funds tracked by Wall St. Rank hold BCLI as of Q4 2023.

  • John Overdeck reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2023 after selling out during the quarter.
  • John Overdeck sold 5,145 BRAINSTORM CELL THERAPUTC shares in Q4 2023, an estimated $15.4K.
  • John Overdeck first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2020 and held it in 6 quarters.
  • John Overdeck's BRAINSTORM CELL THERAPUTC position peaked at $446K in Q1 2021.
  • 46 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2023.

Based on Two Sigma Investments's 13F filing for Q4 2023, filed 14 Feb 2024.